Literature DB >> 28159773

Corticosteroids and infliximab impair the performance of interferon-γ release assays used for diagnosis of latent tuberculosis.

Alexander Edwards1, Yifang Gao2,3, Raymond N Allan1,4, Darran Ball4, Hans de Graaf1,4,5, Tracy Coelho1,6, Vanessa Clifford7, Nigel Curtis7, Anthony Williams2,3,8,9, Saul N Faust1,4,10,11, Salah Mansour1, Ben Marshall1,10,12, Paul Elkington1,10,12, Marc Tebruegge1,7,10,11.   

Abstract

The impact of immunosuppression on interferon-γ release assays and novel cytokine biomarkers of TB infection, mycobacteria-specific IL-2, IP-10 and TNF-α responses was investigated in an ex vivo model. Cytokine responses in standard QuantiFERON-TB Gold in-Tube (QFT-GIT) assays were compared with duplicate assays containing dexamethasone or infliximab. Dexamethasone converted QFT-GIT results from positive to negative in 30% of participants. Antigen-stimulated interferon-γ, IL-2 and TNF-α responses were markedly reduced, but IP-10 responses were preserved. Infliximab caused QFT-GIT result conversion in up to 30% of participants and substantial reductions in all cytokine responses. Therefore, corticosteroids and anti-TNF-α agents significantly impair interferon-γ release assay performance. IP-10 may be a more robust TB biomarker than interferon-γ in patients receiving corticosteroids. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Tuberculosis

Mesh:

Substances:

Year:  2017        PMID: 28159773     DOI: 10.1136/thoraxjnl-2016-209397

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  12 in total

1.  Calcineurin Inhibitors and Variation in the Performance of Interferon-γ Release Assays Used to Detect Tuberculosis Infection.

Authors:  Edward Barton; Yifang Gao; Darran Ball; Katy Fidler; Nigel Klein; Nigel Curtis; Vanessa Clifford; Ben G Marshall; Andrew Chancellor; Salah Mansour; Paul Elkington; Marc Tebruegge
Journal:  Ann Am Thorac Soc       Date:  2019-06

Review 2.  Moving towards personalized treatments of immune-related adverse events.

Authors:  Khashayar Esfahani; Arielle Elkrief; Cassandra Calabrese; Réjean Lapointe; Marie Hudson; Bertrand Routy; Wilson H Miller; Leonard Calabrese
Journal:  Nat Rev Clin Oncol       Date:  2020-04-03       Impact factor: 66.675

3.  Preserved in vitro immunoreactivity in children receiving long-term immunosuppressive therapy due to inflammatory bowel disease or autoimmune hepatitis.

Authors:  Teresa Schleker; Eva-Maria Jacobsen; Benjamin Mayer; Gudrun Strauss; Klaus-Michael Debatin; Carsten Posovszky
Journal:  Mol Cell Pediatr       Date:  2018-01-19

4.  Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Authors:  Massimo Amicosante; Lia D'Ambrosio; Marcela Munoz; Fernanda Carvalho de Queiroz Mello; Marc Tebruegge; Novel Njweipi Chegou; Fouad Seghrouchni; Rosella Centis; Delia Goletti; Graham Bothamley; Giovanni Battista Migliori
Journal:  J Bras Pneumol       Date:  2017 Sep-Oct       Impact factor: 2.624

5.  Risk Factors for Indeterminate Interferon-Gamma Release Assay for the Diagnosis of Tuberculosis in Children-A Systematic Review and Meta-Analysis.

Authors:  Noëmi R Meier; Thomas Volken; Marc Geiger; Ulrich Heininger; Marc Tebruegge; Nicole Ritz
Journal:  Front Pediatr       Date:  2019-05-29       Impact factor: 3.418

6.  Tuberculosis Infection in Women of Reproductive Age: A Cross-sectional Study at Antenatal Care Clinics in an Ethiopian City.

Authors:  John Walles; Fregenet Tesfaye; Marianne Jansson; Taye Tolera Balcha; Erik Sturegård; Mestawet Kefeni; Gadissa Merga; Stefan R Hansson; Niclas Winqvist; Per Björkman
Journal:  Clin Infect Dis       Date:  2021-07-15       Impact factor: 9.079

7.  Immune-mediated inflammatory diseases differently affect IGRAs' accuracy for latent tuberculosis infection diagnosis in clinical practice.

Authors:  Irene Latorre; Sonia Mínguez; José-Manuel Carrascosa; Juan Naves; Raquel Villar-Hernández; Beatriz Muriel; Cristina Prat; Esther García-García; Irma Casas; Eugeni Domènech; Carlos Ferrándiz; Lourdes Mateo; Jose Domínguez
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

8.  Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.

Authors:  Jieun Kang; Dae Hyun Jeong; Minkyu Han; Suk-Kyun Yang; Jeong-Sik Byeon; Byong Duk Ye; Sang Hyoung Park; Sung Wook Hwang; Tae Sun Shim; Kyung-Wook Jo
Journal:  J Korean Med Sci       Date:  2018-10-23       Impact factor: 2.153

9.  Testing for Mycobacterium tuberculosis infection using the QuantiFERON-TB GOLD assay in patients with comorbid conditions in a tertiary care endemic setting.

Authors:  Kiran Iqbal Masood; Bushra Jamil; Alnoor Akber; Maheen Hassan; Muniba Islam; Zahra Hasan
Journal:  Trop Dis Travel Med Vaccines       Date:  2020-02-19

10.  Tuberculosis screening in multiple sclerosis: effect of disease-modifying therapies and lymphopenia on the prevalence of indeterminate TB screening results in the clinical setting.

Authors:  Laura E Baldassari; Jenny Feng; Gabrielle Macaron; Sarah M Planchon; Ebtesam Alshehri; Brandon P Moss; Daniel Ontaneda; Mary A Willis
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-09-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.